An extensive report on the Sixth International Workshop on Clinical Pharmacology of HIV Therapy by Mark Mascolini is now available at www.hivpresentation.com. Highlights of the workshop report include:
- Results of the POPIN study: a randomised study of 122 patients taking either PIs or NNRTIs found no significant virologic or safety benefit to therapeutic drug monitoring plus adherence intervention when compared with standard of care.
- Once daily protease inhibitor dosing may be more risky than twice daily dosing: missing a single daily PI dose is the equivalent of missing three consecutive twice daily doses.
- Cases of CD4 decline or blunted CD4 cell recovery have already been reported in people taking tenofovir with ddI. Now a small number of cases have been reported in patients who combined tenofovir with abacavir. Is it a drug interaction?
- Dose adjustment needed with maraviroc: dose reduction with PIs, dose increase with efavirenz.
Presentations, posters and abstracts from the meeting are also available at the same website.